Humacyte, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Humacyte, Inc. (HUMA) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2025-03-31
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2024-12-31 was $0.00.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2024-09-30 was $0.00.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-09-30 was $0.00.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $2.11M, a 86.83% decline from fiscal 2022.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $16.00M.
- Humacyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2021 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $2.11M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.11M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $2.11M 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $8.00M derived: sum of 2 quarters · filed 2024-03-28 | $16.00M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $8.00M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $8.00M 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |